1921
Volume 93, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

In non-endemic countries, leprosy, or Hansen's disease (HD), remains rare and is often underrecognized. Consequently, the literature is currently lacking in clinical descriptions of leprosy complications in the United States. Immune-mediated inflammatory states known as reactions are common complications of HD. Type 1 reactions are typical of borderline cases and occur in 30% of patients and present as swelling and inflammation of existing skin lesions, neuritis, and nerve dysfunction. Type 2 reactions are systemic events that occur at the lepromatous end of the disease spectrum, and typical symptoms include fever, arthralgias, neuritis, and classic painful erythematous skin nodules known as erythema nodosum leprosum. We report three patients with lepromatous leprosy seen at a U.S. HD clinic with complicated type 2 reactions. The differences in presentations and clinical courses highlight the complexity of the disease and the need for increased awareness of unique manifestations of lepromatous leprosy in non-endemic areas.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.15-0052
2015-11-04
2017-09-24
Loading full text...

Full text loading...

/deliver/fulltext/14761645/93/5/1082.html?itemId=/content/journals/10.4269/ajtmh.15-0052&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2012. Global leprosy situation, 2012. Wkly Epidemiol Rec 87: 317328.
  2. Rodrigues LC, Lockwood DNJ, , 2011. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis 11: 464470.[Crossref]
  3. White C, Franco-Paredes C, , 2015. Leprosy in the 21st century. Clin Microbiol Rev 28: 8094.[Crossref]
  4. Job CK, Jayakumar J, Kearney M, Gillis TP, , 2008. Transmission of leprosy: a study of skin and nasal secretions of household contacts of leprosy patients using PCR. Am J Trop Med Hyg 78: 518521.
  5. Zhang F, Chen S, Sun Y, Chu T, , 2009. Healthcare seeking behaviour and delay in diagnosis of leprosy in a low endemic area of China. Lepr Rev 80: 416423.
  6. Bhat RM, Prakash C, , 2012. Leprosy: an overview of pathophysiology. Interdiscip Perspect Infect Dis 2012: 6.
  7. Walker SL, Lockwood DN, , 2008. Leprosy type 1 (reversal) reactions and their management. Lepr Rev 79: 372386.
  8. Legendre DP, Muzny CA, Swiatlo E, , 2012. Hansen's disease (leprosy): current and future pharmacotherapy and treatment of disease-related immunologic reactions. Pharmacotherapy 32: 2737.[Crossref]
  9. Rattan R, Shanker V, Tegta GR, Verma GK, , 2009. Severe form of type 2 reaction in patients of Hansen's disease after withdrawal of thalidomide: case reports. Indian J Lepr 81: 199203.
  10. Mendiratta V, Malik M, Gurtoo A, Chander R, , 2014. Fulminant hepatic failure in a 15 year old boy with borderline lepromatous leprosy and type 2 reaction. Lepr Rev 8: 5457.
  11. Naveen KN, Athanikar SB, Hegde SP, Athanikar VS, , 2014. Livedo reticularis in type 2 lepra reaction: a rare presentation. Indian Dermatol Online J 5: 182184.[Crossref]
  12. Singh SK, Sharma T, Rai T, Prabhu A, , 2014. Type 2 lepra reaction in an immunocompromised patient precipitated by filariasis. Indian J Sex Transm Dis 35: 4042.[Crossref]
  13. Kamath S, Vaccaro SA, Rea TH, Ochoa MT, , 2014. Recognizing and managing the immunologic reactions in leprosy. J Am Acad Dermatol 71: 795803.[Crossref]
  14. Kahawita IP, Lockwood DNJ, , 2008. Towards understanding the pathology of erythema nodosum leprosum. Trans R Soc Trop Med Hyg 102: 329337.[Crossref]
  15. Mabalay MC, Helwig EB, Tolentino JG, Binford CH, , 1965. The histopathology and histochemistry of erythema nodosum leprosum. Int J Lepr 33: 2849.
  16. Silva EA, Iyer A, Ura S, Lauris JR, Naafs B, Das PK, Vilani-Moreno F, , 2007. Utility of measuring serum levels of anti-PGL-I antibody, neopterin and C-reactive protein in monitoring leprosy patients during multi-drug treatment and reactions. Trop Med Int Health 12: 14501458.[Crossref]
  17. Memon RA, Hussain R, Raynes JG, Lateff A, Chiang TJ, , 1996. Alterations in serum lipids in lepromatous leprosy patients with and without ENL reactions and their relationship to acute phase proteins. Int J Lepr Other Mycobact Dis 64: 115122.
  18. Wemambu SN, Turk JL, Waters MF, Rees RJ, , 1969. Erythema nodosum leprosum: a clinical manifestation of the arthus phenomenon. Lancet 2: 933935.[Crossref]
  19. Ridley MJ, Ridley DS, , 1983. The immunopathology of erythema nodosum leprosum: the role of extravascular complexes. Lepr Rev 54: 95107.
  20. Sharma VK, Saha K, Sehgal VN, , 1982. Serum immunoglobulins an autoantibodies during and after erythema nodosum leprosum (ENL). Int J Lepr Other Mycobact Dis 50: 159163.
  21. Laal S, Bhutani LK, Nath I, , 1985. Natural emergence of antigen-reactive T cells in lepromatous leprosy patients during erythema nodosum leprosum. Infect Immun 50: 887892.
  22. Abdallah M, Attia EA, Saad AA, El-Khateeb EA, Lotfi RA, Abdallah M, El-Shennawy D, , 2014. Serum Th1/Th2 and macrophage lineage cytokines in leprosy; correlation with circulating CD4+ CD25high FoxP3+ T-regs cells. Exp Dermatol 23: 742747.[Crossref]
  23. Walker SL, Waters MF, Lockwood DN, , 2007. The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev 78: 197215.
  24. Sheskin J, , 1965. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 6: 303306.[Crossref]
  25. World Health Organization, 2015. WHO Guidelines for the Management of Severe Erythema Nodosum Leprosum (ENL) Reactions. Geneva, Switzerland: World Health Organization.
  26. Patnaik JK, Saha PK, Satpathy SK, Das BS, Bose TK, , 1989. Hepatic morphology in reactional states of leprosy. Int J Lepr Other Mycobact Dis 57: 499505.
  27. Bullock WE, , 1978. Leprosy: a model of immunological perturbation in chronic infection. J Infect Dis 137: 341354.[Crossref]
  28. Liu TC, Qiu JS, , 1984. Pathological findings on peripheral nerves, lymph nodes, and visceral organs of leprosy. Int J Lepr Other Mycobact Dis 52: 377383.
  29. Rea TH, Bevans L, Taylor CR, , 1980. The histopathology of the spleen from a patient with lepromatous leprosy. Int J Lepr Other Mycobact Dis 48: 285290.
  30. Shen J, Liu M, Zhou M, Wengzhong L, , 2009. Occurrence and management of leprosy reaction in China in 2005. Lepr Rev 80: 164169.
  31. Levy L, Fasal P, Levan N, Freedman R, , 1973. Treatment of erythema nodosum leprosum with thalidomide. Lancet 302: 324325.[Crossref]
  32. Walker SL, Lebas E, Doni SN, Lockwood DN, Lambert SM, , 2014. The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospital-based study. PLoS Negl Trop Dis 8: e2690.[Crossref]
  33. Voorend CGN, Post EB, , 2013. A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction. PLoS Negl Trop Dis 7: e2440.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.15-0052
Loading
/content/journals/10.4269/ajtmh.15-0052
Loading

Data & Media loading...

  • Received : 20 Jan 2015
  • Accepted : 01 Jul 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error